Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)
Open-label phase II, single arm, multicenter study with safety run-in to evaluate the efficacy and safety of Azacitidine combined with Venetoclax in patients with higher-risk chronic myelomonocytic leukemia
Chronic Myeloid Leukemia
DRUG: Venetoclax
Safety run-in, Determination of dose-limiting toxicities within the first two cycles of treatment, after 2 cycles of treatment of the safety run-in phase patients (each cycle is 28 days)|Overall response rate, Overall response encompasses complete remission, partial remission, marrow response and clinical benefit according to protocol-defined criteria modified from MDS/MPN IWG criteria after 3 and 6 cycles of treatment, after 3 and 6 cycles of treatment of the phase II patients (each cycle is 28 days)
Complete remission rate, Complete remission according to protocol-defined criteria modified from MDS/MPN IWG criteria after 3 and 6 cycles of treatment, after 3 and 6 cycles of treatment (each cycle is 28 days)|Overall response rate at best response, Overall response (complete remission, partial remission, marrow response, clinical benefit) according to protocol-defined criteria modified from MDS/MPN IWG criteria at best response, through study completion, an average of 5 years|Overall response rate after 3 and 6 cycles of treatment, Overall response (complete remission, partial remission, marrow response, clinical benefit) according to the DACOTA trial response criteria after 3 and 6 cycles of treatment, after 3 and 6 cycles of treatment (each cycle is 28 days)|Duration of response, Duration of response defined as the time interval between the first date of achievement of any response according to MDS/MPN IWG criteria to progressive disease, through study completion, an average of 5 years|Identification and grading of adverse events, Safety profile, both hematological and non-hematological of treatment (Venetoclax combined with Azacitidine) including identification and grading of adverse events based on NCI CTCAE version 5.0, through study completion, an average of 5 years|Overall survival, Overall survival defined as the time from inclusion until death or end of follow-up, through study completion, an average of 5 years|Acute Myeloid Leukemia (AML)-free survival, AML-free survival defined as the time from inclusion to transformation to AML according to WHO 2016 criteria, death or end of follow-up, whichever occurs first, through study completion, an average of 5 years|Progression-free survival, Progression-free survival defined as the time from inclusion to progressive disease according to MDS/MPN IWG criteria, transformation to AML, death or end of follow-up, whichever occurs first, through study completion, an average of 5 years|Event-free survival, Event-free survival defined as the time from inclusion to failure to achieve any response according to MDS/MPN IWG criteria at the 6-cycle evaluation, occurence of progressive disease according to MDS/MPN IWG criteria, transformaion to AML, or death, whichever occurs first, through study completion, an average of 5 years|Cumulative incidence of AML and cumulative risk of death without AML, Cumulative incidence of AML and cumulative risk of death without AML, considering death and transformation to AML as competing risk, through study completion, an average of 5 years|Cumulative incidence of progressive disease or transformation to AML and cumulative risk of death without progression or AML, Cumulative incidence of progressive disease or transformation to AML and cumulative risk of death without progression or AML, through study completion, an average of 5 years|Rate of Hematopoietic Stem Cell Transplantation (HSCT), Rate of Hematopoietic Stem Cell Transplantation (HSCT) and post-HSCT ovrall survival and AML-free survival, through study completion, an average of 5 years|Survival censoring at Hematopoietic Stem Cell Transplantation (HSCT), Overall survival, AML-free survival and progressive-free survival censoring at Hematopoietic Stem Cell Transplantation (HSCT), through study completion, an average of 5 years|Subsequent therapy, Rate and description of subsequent therapy, through study completion, an average of 5 years|Survival censoring to subsequent therapy, Overall survival, AML-free survival and progressive-free survival censoring at subsequent therapy, through study completion, an average of 5 years
Patient reported outcomes, Patient reported outcomes according to the Myeloproliferative Neoplasm Safety Assessment Form Total Symptom Score which is a 10-item instrument designed to monitor clinically relevant symptoms among patients with myeloproliferative neoplasm. The score has possible range of 0 to 100., through study completion, an average of 5 years|Exploratory endpoints, Biomarkers including somatic mutations by targeted sequencing and BH3 profiling CD34+ cells and monocytes, through study completion, an average of 5 years
AVENHIR trial is an open-label phase II, single arm, multicenter study with safety run-in to evaluate the efficacy and safety of the combination of Azacitidine and Venetoclax in, hypomethylating agent-na√Øve, higher-risk chronic myelomonocytic leukemia patients